Trials / Unknown
UnknownNCT04569227
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Enzychem Lifesciences Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EC-18 | 2000 mg PO daily |
| DRUG | Placebo | PO daily |
Timeline
- Start date
- 2021-04-30
- Primary completion
- 2021-09-01
- Completion
- 2021-11-01
- First posted
- 2020-09-29
- Last updated
- 2021-06-10
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04569227. Inclusion in this directory is not an endorsement.